We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Tests Predicts the Risk of Liver Cirrhosis

By LabMedica International staff writers
Posted on 15 Jul 2020
Fat accumulation in the liver is common and is often seen in people with obesity or diabetes. More...
In the worst case, fatty liver can lead to cirrhosis or liver cancer. It is unusual for this to occur but in those affected, symptoms often only occur at a late stage when there is no available treatment.

The gold standard for diagnosing fibrosis is liver biopsy, which is not reasonable to use as a screening tool in larger populations, expressly in a general population or primary care setting. Several non-invasive scores have been developed to identify individuals with prevalent advanced fibrosis. The Fibrosis-4 (FIB-4) scoring system is often used to estimate the risk of advanced fibrosis in liver diseases.

Hepatology Specialists at the Karolinska University Hospital (Stockholm, Sweden) and their colleagues tested the general hypothesis that repeated measurements of the commonly used FIB-4 index (FIB-4) would improve the identification of individuals at risk of severe liver disease compared with a single measurement. The investigators used the AMORIS cohort that contains laboratory test data in a very large population, surveyed between 1985 and 1996. More than 40,000 people had blood test data for FIB-4 from several sampling occasions. They were followed in national registers to identify those who developed cirrhosis after up to 27 years.

All laboratory analyses were conducted on fresh blood serum samples (53% after overnight fasting) using a uniform and well-documented methodology. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined with an enzymatic UV test and Gamma-glutamyltransferase (GGT) by an enzymatic colorimetric test using a Technicon DAX 96 Multichannel Analyzer (Technicon Instruments Corp., Tarrytown, NY, USA). Glucose levels were analyzed with an enzyme colorimetric technique (glucose oxidase/peroxidase, GOD-PAP) using an AutoChemist-PRISMA automated multichannel analyzers (New Clinicon, Stockholm, Sweden).

The scientists reported that an increase of one unit in FIB-4 was associated with an elevated risk of severe liver disease (adjusted Hazard ratio [aHR] = 1.81). Transitioning from a low- or intermediate- to a high-risk group was associated with an increased risk of severe liver disease compared with those consistently in the low-risk group (aHR = 7.99 and 8.64, respectively). A particularly increased risk of severe liver disease was found in persons defined as high-risk at both tests (aHR=17.04). However, almost half of all events occurred in those consistently in the low-risk group.

Hannes Hagström, MD, PhD, a Consultant in Hepatology and lead author of the study, said, “It is difficult to predict the risk of cirrhosis, although you can get some guidance in using regular blood tests that measure liver damage. We showed that this biomarker is useful for identifying people in primary care with an increased risk of cirrhosis who may need to be more carefully investigated and to exclude people who do not need this. But the method needs to be further developed to reduce the risk of false positive findings, which can lead to unnecessary examinations in healthy people.”

The authors concluded that repeated testing of FIB-4 within five years improves the identification of individuals in the general population at an increased risk of severe liver disease. The study was published on July 1, 2020 in the Journal of Hepatology.

Related Links:
Karolinska University Hospital
Technicon Instruments Corp
New Clinicon



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.